Show simple item record

dc.creatorBakadia, Bianza Moise
dc.creatorHe, Feng
dc.creatorSouho, Tiatou
dc.creatorLamboni, Lallepak
dc.creatorWajid Ullah, Muhammad
dc.creatorBoni, Biaou Ode
dc.creatorQaed Ahmed, Abeer Ahmed
dc.creatorMukole, Biampata Mutu
dc.creatorYang, Guang
dc.date.accessioned2020-11-17T14:58:21Z
dc.date.available2020-11-17T14:58:21Z
dc.date.created2020
dc.identifier.issn0753-3322spa
dc.identifier.otherhttps://doi.org/10.1016/j.biopha.2020.111008spa
dc.identifier.urihttp://hdl.handle.net/20.500.12010/15715
dc.description.abstractThe ongoing pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) has drawn the attention of researchers and clinicians from several disciplines and sectors who are trying to find durable solutions both at preventive and treatment levels. To date, there is no approved effective treatment or vaccine available to control the coronavirus disease-2019 (COVID-19). The preliminary in vitro studies on viral infection models showed potential antiviral activities of type I and III interferons (IFNs), chloroquine (CQ)/hydroxychloroquine (HCQ), and azithromycin (AZM); however, the clinical studies on COVID-19 patients treated with CQ/HCQ and AZM led to controversies in different regions due to their adverse side effects, as well as their combined treatment could prolong the QT interval. Interestingly, the treatment with type I IFNs showed encouraging results. Moreover, the different preliminary reports of COVID-19 candidate vaccines showcase promising results by inducing the production of a high level of neutralizing antibodies (NAbs) and specific T cell-mediated immune response in almost all participants. The present review aims to summarize and analyze the recent progress evidence concerning the use of IFNs, CQ/HCQ, and AZM for the treatment of COVID-19. The available data on immunization options to prevent the COVID-19 are also analyzed with the aim to present the promising options which could be investigated in future for sustainable control of the pandemic.spa
dc.format.extent82 páginasspa
dc.format.mimetypeapplication/pdfspa
dc.language.isoengspa
dc.publisherhttps://doi.org/10.1016/j.biopha.2020.111008spa
dc.sourcereponame:Expeditio Repositorio Institucional UJTLspa
dc.sourceinstname:Universidad de Bogotá Jorge Tadeo Lozanospa
dc.subjectCOVID-19spa
dc.subjectTreatmentspa
dc.subjectInterferonsspa
dc.subjectChloroquine/hydroxychloroquinespa
dc.subjectAzithromycinspa
dc.subjectVaccinespa
dc.titlePrevention and treatment of COVID-19: focus on interferons, chloroquine/hydroxychloroquine, azithromycin, and vaccinespa
dc.type.localArtículospa
dc.subject.lembSíndrome respiratorio agudo gravespa
dc.subject.lembCOVID-19spa
dc.subject.lembSARS-CoV-2spa
dc.subject.lembCoronavirusspa
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.type.hasversioninfo:eu-repo/semantics/acceptedVersionspa
dc.rights.localAbierto (Texto Completo)spa
dc.identifier.doihttps://doi.org/10.1016/j.biopha.2020.111008spa
dc.type.coarhttp://purl.org/coar/resource_type/c_2df8fbb1spa


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record